ID   SV2A_RAT                Reviewed;         742 AA.
AC   Q02563; Q58DZ8;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   13-JUN-2006, sequence version 2.
DT   02-OCT-2024, entry version 175.
DE   RecName: Full=Synaptic vesicle glycoprotein 2A;
DE            Short=Synaptic vesicle protein 2;
DE            Short=Synaptic vesicle protein 2A;
GN   Name=Sv2a; Synonyms=Sv2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA], AND GLYCOSYLATION.
RX   PubMed=1355409; DOI=10.1016/0092-8674(92)90319-8;
RA   Feany M.B., Lee S., Edwards R.H., Buckley K.M.;
RT   "The synaptic vesicle protein SV2 is a novel type of transmembrane
RT   transporter.";
RL   Cell 70:861-867(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 177-194 AND 372-381, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=1426240; DOI=10.1016/0014-5793(92)80917-6;
RA   Gingrich J.A., Andersen P.H., Tiberi M., el Mestikawy S., Jorgensen P.N.,
RA   Fremeau R.T. Jr., Caron M.G.;
RT   "Identification, characterization, and molecular cloning of a novel
RT   transporter-like protein localized to the central nervous system.";
RL   FEBS Lett. 312:115-122(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 1-40.
RC   TISSUE=Brain;
RX   PubMed=1519064; DOI=10.1126/science.1519064;
RA   Bajjalieh S.M., Peterson K., Shingal R., Scheller R.H.;
RT   "SV2, a brain synaptic vesicle protein homologous to bacterial
RT   transporters.";
RL   Science 257:1271-1273(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SYT1.
RX   PubMed=8910372; DOI=10.1074/jbc.271.44.27770;
RA   Schivell A.E., Batchelor R.H., Bajjalieh S.M.;
RT   "Isoform-specific, calcium-regulated interaction of the synaptic vesicle
RT   proteins SV2 and synaptotagmin.";
RL   J. Biol. Chem. 271:27770-27775(1996).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10625067; DOI=10.1016/s0306-4522(99)00370-x;
RA   Janz R., Suedhof T.C.;
RT   "SV2C is a synaptic vesicle protein with an unusually restricted
RT   localization: anatomy of a synaptic vesicle protein family.";
RL   Neuroscience 94:1279-1290(1999).
RN   [7]
RP   INTERACTION WITH AP-2.
RX   PubMed=10455054; DOI=10.1126/science.285.5431.1268;
RA   Haucke V., De Camilli P.;
RT   "AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic
RT   motifs.";
RL   Science 285:1268-1271(1999).
RN   [8]
RP   PHOSPHORYLATION BY CK1, AND INTERACTION WITH SYT1.
RX   PubMed=10747945; DOI=10.1074/jbc.m000674200;
RA   Pyle R.A., Schivell A.E., Hidaka H., Bajjalieh S.M.;
RT   "Phosphorylation of synaptic vesicle protein 2 modulates binding to
RT   synaptotagmin.";
RL   J. Biol. Chem. 275:17195-17200(2000).
RN   [9]
RP   CHARACTERIZATION AS BINDING-SITE FOR ANTIEPILEPTIC DRUG LEVETIRACETAM.
RX   PubMed=15210974; DOI=10.1073/pnas.0308208101;
RA   Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M.,
RA   Matagne A., Fuks B.;
RT   "The synaptic vesicle protein SV2A is the binding site for the
RT   antiepileptic drug levetiracetam.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:9861-9866(2004).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16306227; DOI=10.1242/jcs.02658;
RA   Iezzi M., Theander S., Janz R., Loze C., Wollheim C.B.;
RT   "SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-
RT   evoked granule recruitment.";
RL   J. Cell Sci. 118:5647-5660(2005).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH SYT1.
RX   PubMed=15866046; DOI=10.1016/j.mcn.2004.12.011;
RA   Schivell A.E., Mochida S., Kensel-Hammes P., Custer K.L., Bajjalieh S.M.;
RT   "SV2A and SV2C contain a unique synaptotagmin-binding site.";
RL   Mol. Cell. Neurosci. 29:56-64(2005).
RN   [12]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE A RECEPTOR (MICROBIAL INFECTION),
RP   SUBUNIT (MICROBIAL INFECTION), AND DISRUPTION PHENOTYPE.
RX   PubMed=16543415; DOI=10.1126/science.1123654;
RA   Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R.;
RT   "SV2 is the protein receptor for botulinum neurotoxin A.";
RL   Science 312:592-596(2006).
RN   [13]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPES A AND E RECEPTOR (MICROBIAL
RP   INFECTION), SUBUNIT (MICROBIAL INFECTION), GLYCOSYLATION AT ASN-498;
RP   ASN-548 AND ASN-573, AND MUTAGENESIS OF ASN-498; ASN-548; 570-ARG--ASN-573
RP   AND ASN-573.
RX   PubMed=18815274; DOI=10.1091/mbc.e08-07-0765;
RA   Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R.;
RT   "Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E
RT   into neurons.";
RL   Mol. Biol. Cell 19:5226-5237(2008).
RN   [14]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE F RECEPTOR (MICROBIAL INFECTION),
RP   SUBUNIT (MICROBIAL INFECTION), AND GLYCOSYLATION.
RX   PubMed=19476346; DOI=10.1021/bi9002138;
RA   Fu Z., Chen C., Barbieri J.T., Kim J.J., Baldwin M.R.;
RT   "Glycosylated SV2 and gangliosides as dual receptors for botulinum
RT   neurotoxin serotype F.";
RL   Biochemistry 48:5631-5641(2009).
RN   [15]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPES A; E AND F RECEPTOR (MICROBIAL
RP   INFECTION), AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=19650874; DOI=10.1111/j.1471-4159.2009.06298.x;
RA   Rummel A., Haefner K., Mahrhold S., Darashchonak N., Holt M., Jahn R.,
RA   Beermann S., Karnath T., Bigalke H., Binz T.;
RT   "Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding
RT   site prior to stimulation-dependent uptake with botulinum neurotoxin F
RT   utilising the three isoforms of SV2 as second receptor.";
RL   J. Neurochem. 110:1942-1954(2009).
RN   [16]
RP   POSSIBLE FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE D RECEPTOR (MICROBIAL
RP   INFECTION), AND MUTAGENESIS OF 196-ASP--SER-200; 321-SER--HIS-331; ASN-498;
RP   ASN-548 AND ASN-573.
RX   PubMed=21483489; DOI=10.1371/journal.ppat.1002008;
RA   Peng L., Tepp W.H., Johnson E.A., Dong M.;
RT   "Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides
RT   as receptors.";
RL   PLoS Pathog. 7:E1002008-E1002008(2011).
RN   [17]
RP   NOT RECEPTOR FOR C.BOTULINUM NEUROTOXIN TYPE D (MICROBIAL INFECTION), AND
RP   SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=21632541; DOI=10.1074/jbc.m111.254086;
RA   Kroken A.R., Karalewitz A.P., Fu Z., Kim J.J., Barbieri J.T.;
RT   "Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into
RT   neurons.";
RL   J. Biol. Chem. 286:26828-26837(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127 AND SER-393, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-573, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=24090084; DOI=10.1021/pr400783j;
RA   Parker B.L., Thaysen-Andersen M., Solis N., Scott N.E., Larsen M.R.,
RA   Graham M.E., Packer N.H., Cordwell S.J.;
RT   "Site-specific glycan-peptide analysis for determination of N-glycoproteome
RT   heterogeneity.";
RL   J. Proteome Res. 12:5791-5800(2013).
RN   [20]
RP   FUNCTION AS C.BOTULINUM NEUROTOXIN TYPE A2 RECEPTOR (MICROBIAL INFECTION),
RP   SUBUNIT (MICROBIAL INFECTION), AND GLYCOSYLATION.
RX   PubMed=29649119; DOI=10.3390/toxins10040153;
RA   Gustafsson R., Zhang S., Masuyer G., Dong M., Stenmark P.;
RT   "Crystal structure of botulinum neurotoxin A2 in complex with the human
RT   protein receptor SV2C reveals plasticity in receptor binding.";
RL   Toxins 10:0-0(2018).
CC   -!- FUNCTION: Plays a role in the control of regulated secretion in neural
CC       and endocrine cells, enhancing selectively low-frequency
CC       neurotransmission. Positively regulates vesicle fusion by maintaining
CC       the readily releasable pool of secretory vesicles.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type A (BoNT/A, botA); the toxin binds via extracellular loop 4
CC       (PubMed:16543415). Restores uptake of BoNT/A in mouse cells that are
CC       deleted for SV2 receptor (PubMed:16543415, PubMed:18815274).
CC       Glycosylation of Asn-573 is not essential for receptor activity, but
CC       enhances uptake (PubMed:18815274, PubMed:19650874). Also serves as a
CC       receptor for the closely related C.botulinum neurotoxin type A2;
CC       glycosylation is not essential but enhances the interaction
CC       (PubMed:29649119). {ECO:0000269|PubMed:16543415,
CC       ECO:0000269|PubMed:18815274, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:29649119}.
CC   -!- FUNCTION: Possible receptor for C.botulinum neurotoxin type D (BoNT/D,
CC       botD); BoNT/D does not bind to extracellular loop 4 as do BoNT/A and
CC       BoNT/E, nor to loop 1 or loop 3 (PubMed:21483489). Another group does
CC       not find a convincing interaction with SV2 (PubMed:21632541).
CC       {ECO:0000269|PubMed:21483489, ECO:0000269|PubMed:21632541}.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type E (BoNT/E); the toxin probably binds via extracellular loop 4 and
CC       requires glycosylation of Asn-573 (PubMed:18815274, PubMed:19650874).
CC       Restores uptake of BoNT/E in mouse cells that are deleted for SV2
CC       receptor (PubMed:18815274). {ECO:0000269|PubMed:18815274,
CC       ECO:0000269|PubMed:19650874}.
CC   -!- FUNCTION: (Microbial infection) Receptor for C.botulinum neurotoxin
CC       type F (BoNT/F) (PubMed:19476346, PubMed:19650874). Binding requires
CC       glycosylation of Asn-573 (PubMed:19476346).
CC       {ECO:0000269|PubMed:19650874, ECO:0000305|PubMed:19476346}.
CC   -!- SUBUNIT: Interacts with SYT1/synaptotagmin-1 in a calcium-dependent
CC       manner. Binds the adapter protein complex AP-2.
CC       {ECO:0000269|PubMed:10455054, ECO:0000269|PubMed:10747945,
CC       ECO:0000269|PubMed:15866046, ECO:0000269|PubMed:8910372}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.botulinum neurotoxin
CC       type A1 and type A2 (BoNT/A, botA) (PubMed:16543415, PubMed:19650874,
CC       PubMed:21483489, PubMed:21632541, PubMed:29649119). Interaction is
CC       improved by glycosylation of SV2 (PubMed:29649119).
CC       {ECO:0000269|PubMed:16543415, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:21483489, ECO:0000269|PubMed:21632541,
CC       ECO:0000269|PubMed:29649119}.
CC   -!- SUBUNIT: (Microbial infection) Copurifies with C.botulinum neurotoxin
CC       type B (BoNT/B, botB) and synaptotagmin 1 (SYT1) (PubMed:19476346).
CC       Interaction does not require glycosylation of SV2 or SYT1 proteins
CC       (PubMed:19476346). Another group finds only copurification with SYT1
CC       and SYT2 (PubMed:19650874). {ECO:0000269|PubMed:19476346,
CC       ECO:0000269|PubMed:19650874}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.botulinum neurotoxin
CC       type E (BoNT/E) (PubMed:18815274, PubMed:19476346, PubMed:19650874).
CC       Interaction requires glycosylation of SV2 proteins (PubMed:18815274,
CC       PubMed:19476346, PubMed:19650874). {ECO:0000269|PubMed:18815274,
CC       ECO:0000269|PubMed:19476346, ECO:0000269|PubMed:19650874}.
CC   -!- SUBUNIT: (Microbial infection) Copurifies with C.botulinum neurotoxin
CC       type F (BoNT/F) and synaptotagmin 1 (SYT2) (PubMed:19476346). Another
CC       group finds only copurification with BoNT/F (PubMed:19650874).
CC       Interaction requires SV2 glycosylation (PubMed:19476346).
CC       {ECO:0000269|PubMed:19476346, ECO:0000269|PubMed:19650874}.
CC   -!- INTERACTION:
CC       Q02563; P21707: Syt1; NbExp=2; IntAct=EBI-466194, EBI-458098;
CC       Q02563; O00213: APBB1; Xeno; NbExp=3; IntAct=EBI-466194, EBI-81694;
CC       Q02563; P0DPI0: botA; Xeno; NbExp=2; IntAct=EBI-466194, EBI-8178893;
CC   -!- SUBCELLULAR LOCATION: Presynapse {ECO:0000250|UniProtKB:Q9JIS5}.
CC       Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane
CC       {ECO:0000269|PubMed:10625067, ECO:0000269|PubMed:1426240,
CC       ECO:0000269|PubMed:16306227}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:10625067, ECO:0000269|PubMed:1426240,
CC       ECO:0000269|PubMed:16306227}. Note=Enriched in chromaffin granules, not
CC       present in adrenal microsomes. Associated with both insulin granules
CC       and synaptic-like microvesicles in insulin-secreting cells of the
CC       pancreas. Colocalizes with ATP2B1 at photoreceptor synaptic terminals.
CC       {ECO:0000250|UniProtKB:Q9JIS5, ECO:0000269|PubMed:10625067,
CC       ECO:0000269|PubMed:16306227}.
CC   -!- TISSUE SPECIFICITY: Widely expressed throughout the brain (at protein
CC       level). Expressed by neural and endocrine cells of brain and spinal
CC       cord. {ECO:0000269|PubMed:1426240}.
CC   -!- PTM: Phosphorylation by CK1 of the N-terminal cytoplasmic domain
CC       regulates interaction with SYT1. {ECO:0000269|PubMed:10747945}.
CC   -!- PTM: N-glycosylated, on at least 3 residues.
CC       {ECO:0000269|PubMed:1355409, ECO:0000305|PubMed:18815274,
CC       ECO:0000305|PubMed:19476346, ECO:0000305|PubMed:29649119}.
CC   -!- DISRUPTION PHENOTYPE: Short hairpin-mediated RNA knockdown of the
CC       protein in PC12 cells leads to increased resistance to C.botulinum
CC       neurotoxin type A (BoNT/A, botA) as assayed by reduced SNAP25 cleavage;
CC       uptake and degradation are restored by expression of SV2B or SV2C
CC       (PubMed:16543415). {ECO:0000269|PubMed:16543415}.
CC   -!- MISCELLANEOUS: Identified as the brain binding-site for the
CC       antiepileptic drug levetiracetam/lev.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: The use of this protein as a coreceptor for C.botulinum type D
CC       (BoNT/D, botD) is controversial. In double SV2A/SV2B knockout mice
CC       BoNT/D does not degrade its synaptobrevin target; introducing SV2A,
CC       SV2B or SV2C restores target cleavage (PubMed:21483489). However
CC       another group does not find a convincing interaction with SV2
CC       (PubMed:21632541). {ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:21632541}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L01788; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   EMBL; L05435; AAA42188.1; -; mRNA.
DR   EMBL; BC092132; AAH92132.1; -; mRNA.
DR   PIR; A43344; A43344.
DR   RefSeq; NP_476558.2; NM_057210.2.
DR   RefSeq; XP_006233014.1; XM_006232952.3.
DR   AlphaFoldDB; Q02563; -.
DR   SMR; Q02563; -.
DR   BioGRID; 250772; 2.
DR   IntAct; Q02563; 8.
DR   MINT; Q02563; -.
DR   STRING; 10116.ENSRNOP00000028760; -.
DR   BindingDB; Q02563; -.
DR   ChEMBL; CHEMBL4381; -.
DR   DrugCentral; Q02563; -.
DR   GuidetoPHARMACOLOGY; 2634; -.
DR   TCDB; 2.A.1.22.1; the major facilitator superfamily (mfs).
DR   GlyCosmos; Q02563; 3 sites, 5 glycans.
DR   GlyGen; Q02563; 3 sites, 5 N-linked glycans (1 site).
DR   iPTMnet; Q02563; -.
DR   PhosphoSitePlus; Q02563; -.
DR   SwissPalm; Q02563; -.
DR   jPOST; Q02563; -.
DR   PaxDb; 10116-ENSRNOP00000028760; -.
DR   Ensembl; ENSRNOT00000028760.5; ENSRNOP00000028760.2; ENSRNOG00000021182.6.
DR   Ensembl; ENSRNOT00055055705; ENSRNOP00055045906; ENSRNOG00055032256.
DR   Ensembl; ENSRNOT00060023914; ENSRNOP00060019040; ENSRNOG00060013977.
DR   Ensembl; ENSRNOT00065053497; ENSRNOP00065043972; ENSRNOG00065031025.
DR   GeneID; 117559; -.
DR   KEGG; rno:117559; -.
DR   UCSC; RGD:619715; rat.
DR   AGR; RGD:619715; -.
DR   CTD; 9900; -.
DR   RGD; 619715; Sv2a.
DR   eggNOG; KOG0255; Eukaryota.
DR   GeneTree; ENSGT00950000182940; -.
DR   HOGENOM; CLU_001265_46_15_1; -.
DR   InParanoid; Q02563; -.
DR   OMA; FNDKSMV; -.
DR   OrthoDB; 2615066at2759; -.
DR   PhylomeDB; Q02563; -.
DR   TreeFam; TF324824; -.
DR   PRO; PR:Q02563; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000021182; Expressed in frontal cortex and 17 other cell types or tissues.
DR   GO; GO:0005911; C:cell-cell junction; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0098982; C:GABA-ergic synapse; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0031594; C:neuromuscular junction; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0048786; C:presynaptic active zone; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IDA:MGI.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:SynGO.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IDA:SynGO.
DR   GO; GO:0043195; C:terminal bouton; HDA:ParkinsonsUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0006874; P:intracellular calcium ion homeostasis; ISO:RGD.
DR   GO; GO:0006836; P:neurotransmitter transport; TAS:RGD.
DR   GO; GO:0014052; P:regulation of gamma-aminobutyric acid secretion; IMP:RGD.
DR   GO; GO:0016082; P:synaptic vesicle priming; ISO:RGD.
DR   CDD; cd17439; MFS_SV2A; 1.
DR   Gene3D; 2.160.20.80; E3 ubiquitin-protein ligase SopA; 1.
DR   Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 2.
DR   InterPro; IPR011701; MFS.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   InterPro; IPR022308; SV2.
DR   NCBIfam; TIGR01299; synapt_SV2; 1.
DR   PANTHER; PTHR23511; SYNAPTIC VESICLE GLYCOPROTEIN 2; 1.
DR   PANTHER; PTHR23511:SF11; SYNAPTIC VESICLE GLYCOPROTEIN 2A; 1.
DR   Pfam; PF07690; MFS_1; 1.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; MFS general substrate transporter; 2.
DR   SUPFAM; SSF141571; Pentapeptide repeat-like; 1.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   Cell projection; Cytoplasmic vesicle; Direct protein sequencing;
KW   Glycoprotein; Membrane; Neurotransmitter transport; Phosphoprotein;
KW   Receptor; Reference proteome; Synapse; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..742
FT                   /note="Synaptic vesicle glycoprotein 2A"
FT                   /id="PRO_0000084882"
FT   TOPO_DOM        1..169
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        170..190
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        191..205
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:21483489"
FT   TRANSMEM        206..226
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        227..233
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        234..254
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        255..262
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        263..283
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        284..294
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        295..315
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        316..334
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:21483489"
FT   TRANSMEM        335..355
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        356..447
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        448..468
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        469..598
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:16543415,
FT                   ECO:0000305|PubMed:18815274"
FT   TRANSMEM        599..619
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        620..626
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        627..647
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        648..651
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        652..672
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        673..685
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        686..708
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        709..712
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        713..731
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        732..742
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          1..57
FT                   /note="Interaction with SYT1"
FT   REGION          40..145
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        68..84
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         80
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L0J3"
FT   MOD_RES         81
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L0J3"
FT   MOD_RES         84
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q7L0J3"
FT   MOD_RES         127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         480
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIS5"
FT   CARBOHYD        498
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:18815274"
FT   CARBOHYD        548
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:18815274"
FT   CARBOHYD        573
FT                   /note="N-linked (GlcNAc...) asparagine; alternate"
FT                   /evidence="ECO:0000255, ECO:0000305|PubMed:18815274"
FT   CARBOHYD        573
FT                   /note="N-linked (HexNAc...) asparagine; alternate"
FT                   /evidence="ECO:0007744|PubMed:24090084"
FT   MUTAGEN         196..200
FT                   /note="Missing: No change in uptake of C.botulinum
FT                   neurotoxin type D (BoNT/D, botD) or C.botulinum neurotoxin
FT                   type E (BoNT/E)."
FT                   /evidence="ECO:0000269|PubMed:21483489"
FT   MUTAGEN         321..331
FT                   /note="Missing: No change in uptake of BoNT/D or BoNT/E."
FT                   /evidence="ECO:0000269|PubMed:21483489"
FT   MUTAGEN         498
FT                   /note="N->Q: No change in uptake of BoNT/E or C.botulinum
FT                   neurotoxin type A (BoNT/A, botA) by mouse SV2A/SV2B
FT                   knockout neurons; SV2A apparent molecular weight decreases.
FT                   No change in uptake of BoNT/E; when associated with Q-548.
FT                   No change in uptake of BoNT/D."
FT                   /evidence="ECO:0000269|PubMed:18815274,
FT                   ECO:0000269|PubMed:21483489"
FT   MUTAGEN         548
FT                   /note="N->Q: No change in uptake of BoNT/E or BoNT/A by
FT                   mouse SV2A/SV2B knockout neurons; SV2A apparent molecular
FT                   weight decreases. No change in uptake of BoNT/E; when
FT                   associated with Q-498. No change in uptake of BoNT/D."
FT                   /evidence="ECO:0000269|PubMed:18815274,
FT                   ECO:0000269|PubMed:21483489"
FT   MUTAGEN         570..573
FT                   /note="RLVN->TLVQ: Restores apparent molecular weight to
FT                   wild-type, does not restore uptake of BoNT/E."
FT                   /evidence="ECO:0000269|PubMed:18815274"
FT   MUTAGEN         573
FT                   /note="N->Q: BoNT/E not taken up by mouse SV2A/SV2B
FT                   knockout neurons, decreased uptake of BoNT/A; SV2A apparent
FT                   molecular weight decreases. No change in uptake of BoNT/D."
FT                   /evidence="ECO:0000269|PubMed:18815274,
FT                   ECO:0000269|PubMed:21483489"
FT   CONFLICT        340
FT                   /note="C -> F (in Ref. 1; AAA42188)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   742 AA;  82661 MW;  E10FC62BEEFE316A CRC64;
     MEEGFRDRAA FIRGAKDIAK EVKKHAAKKV VKGLDRVQDE YSRRSYSRFE EEEDDDDFPA
     PADGYYRGEG AQDEEEGGAS SDATEGHDED DEIYEGEYQG IPRAESGGKG ERMADGAPLA
     GVRGGLSDGE GPPGGRGEAQ RRKDREELAQ QYETILRECG HGRFQWTLYF VLGLALMADG
     VEVFVVGFVL PSAEKDMCLS DSNKGMLGLI VYLGMMVGAF LWGGLADRLG RRQCLLISLS
     VNSVFAFFSS FVQGYGTFLF CRLLSGVGIG GSIPIVFSYF SEFLAQEKRG EHLSWLCMFW
     MIGGVYAAAM AWAIIPHYGW SFQMGSAYQF HSWRVFVLVC AFPSVFAIGA LTTQPESPRF
     FLENGKHDEA WMVLKQVHDT NMRAKGHPER VFSVTHIKTI HQEDELIEIQ SDTGTWYQRW
     GVRALSLGGQ VWGNFLSCFS PEYRRITLMM MGVWFTMSFS YYGLTVWFPD MIRHLQAVDY
     AARTKVFPGE RVEHVTFNFT LENQIHRGGQ YFNDKFIGLR LKSVSFEDSL FEECYFEDVT
     SSNTFFRNCT FINTVFYNTD LFEYKFVNSR LVNSTFLHNK EGCPLDVTGT GEGAYMVYFV
     SFLGTLAVLP GNIVSALLMD KIGRLRMLAG SSVLSCVSCF FLSFGNSESA MIALLCLFGG
     VSIASWNALD VLTVELYPSD KRTTAFGFLN ALCKLAAVLG ISIFTSFVGI TKAAPILFAS
     AALALGSSLA LKLPETRGQV LQ
//
